Ultime notizie per OPKO Health (NASDAQ:OPK) Azioni

OPKO HEALTH INC

OPKO Health

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

OPKO Health Inc

Digital Holdings Inc

OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO's common stock has been repurchased under the existing program since its authorization in July 2024.

News

Buybacks

OPKO Health Announces $100M Increase To Its Existing Share Repurchase Program, Bringing The Aggregate Capacity Of The Program To $200M

6 analysts have expressed a variety of opinions on OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $2.75, along with a high estimate of $3.00 and a low estimate of $2.25. The current average, unchanged from the previous average price target, holds steady. 
<img src="https://www.benzinga.com/files/images/story/2025/1742385626_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of OPKO Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$2.25</td>
<td>$2.25</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$2.25</td>
<td>$2.25</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to OPKO Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OPKO Health compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of OPKO Health's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into OPKO Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OPK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on OPKO Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind OPKO Health</h2>
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
<h3>Financial Milestones: OPKO Health's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, OPKO Health showcased positive performance, achieving a revenue growth rate of 0.95% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: OPKO Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.64%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): OPKO Health's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.01%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.63%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.37, OPKO Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 6 Analyst Projections For OPKO Health

HC Wainwright &amp; Co. analyst Yi Chen reiterates OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Buy and maintains $3 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on OPKO Health, Maintains $3 Price Target

Biotech

General

ENTX

OPKO Health And Entera Bio Enter Collaboration Agreement To Advance Oral GLP-1/Glucagon Tablet Candidate Into Clinic For Obesity And Metabolic Disorders; OPKO And Entera Will Hold 60% And 40% Pro-Rata Ownership Interests, Respectively; In Connection With Agreement, OPKO Purchased 3.685M Shares Of Entera At $2.17/Share

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Outperform and maintains $2.25 price target.

Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target

Health Care

Laboratory Corporation Of America Holdings

Labcorp Will Acquire Select Assets Of Bioreference Health, A Wholly Owned Subsidiary Of Opko Health For $225M, Including $192.5M Payable At Closing And Up To $32.5M In An Earnout Based On Performance

OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.09) by 122.22 percent. This is a 122.22 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $183.60 million which beat the analyst consensus estimate of $155.42 million by 18.13 percent. This is a 0.93 percent increase over sales of $181.90 million the same period last year.

Earnings

Earnings Beats

OPKO Health Q4 EPS $0.02 Beats $(0.09) Estimate, Sales $183.60M Beat $155.42M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

HC Wainwright &amp; Co. analyst Yi Chen maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Buy and maintains $3 price target.

HC Wainwright & Co. Maintains Buy on OPKO Health, Maintains $3 Price Target

WIIM

Merck & Compnay and OPKO Health shares are trading higher after the companies announced a license and collaboration agreement to develop an Epstein-Barr virus vaccine.

OPKO Health's ModeX Therapeutics Begins Phase I Trial For Epstein-Barr Virus Vaccine In Collaboration With Merck; First Participant Dosed, Milestone Payment Triggered By Merck

OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. The company reported quarterly sales of $173.600 million which missed the analyst consensus estimate of $181.525 million by 4.37 percent. This is a 2.80 percent decrease over sales of $178.600 million the same period last year.

Earnings Misses

OPKO Health Q3 2024 Adj. EPS $(0.09), Inline, Sales $173.600M Miss $181.525M Estimate

Development Based On ModeX's MSTAR Technology To Prepare For Emerging Viral Threats

ModeX Therapeutics Secures $35M BARDA Supplement For COVID Multispecific Antibodies And $16M For Influenza Program; Total BARDA Awards Now At $110M With Potential To Reach $205M If All Options Are Exercised

Will Support Sales And Marketing Of OPKO Products On Additional E-Commerce Platforms And Social Media Channels; Agreement Includes Exclusive Rights For Japanese Market, One Of The World's Largest E-Commerce Markets With $151B Revenue In 2023

NXPL

NextPlat Secures Four-Year Extension Of OPKO Healthcare E-Commerce Program In China And Expands Program To Japan

Entera Bio And OPKO Health Announce PK/PD Results For Oral Oxyntomodulin Peptide Tablet Candidate, Showing Significant Systemic Exposure And Favorable PK Profile In Obesity And Metabolic Disorder Studies; Oral OXM Demonstrates Prolonged Systemic Exposure Comparable To Semaglutide

Press Releases

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference

NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer

OPKO Health's ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

OPKO Health

Notizie

Ultime notizie per OPKO Health (NASDAQ:OPK) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO